Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2000
09/14/2000WO2000053605A1 Tyrosine kinase inhibitors
09/14/2000WO2000053602A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000053596A2 Imidazole compounds as histamine h3 ligands
09/14/2000WO2000053264A1 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
09/14/2000WO2000053236A2 Methods and compositions for targeted drug delivery
09/14/2000WO2000053232A1 Matriptase, a serine protease and its applications
09/14/2000WO2000053231A2 Fatty acid-anticancer conjugates and uses thereof
09/14/2000WO2000053227A1 Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
09/14/2000WO2000053223A1 Apoptosis inducing molecule ii and methods of use
09/14/2000WO2000053193A1 Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia
09/14/2000WO2000053178A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000053168A2 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
09/14/2000WO2000053167A2 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
09/14/2000WO2000037685A3 Method of identifying a psychotropic agent using differential gene expression
09/14/2000WO2000037068B1 Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
09/14/2000WO2000037065A3 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
09/14/2000WO2000035469A3 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
09/14/2000WO2000035430A3 Homer a new target of treating psychiatric disorders
09/14/2000WO2000035409A3 Hiv-i fusion inhibition compounds
09/14/2000WO2000030587A3 NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES
09/14/2000WO2000023599A3 Human proteins involved in endoplasmic reticulum protein degradation
09/14/2000WO2000022129A9 Non-endogenous, constitutively activated human g protein-coupled receptors
09/14/2000WO2000022125A9 6-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same
09/14/2000WO2000013709A3 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
09/14/2000WO1999066875A3 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism
09/14/2000WO1999065228A3 Pharmaceutical combination used to compensate for a testosterone deficiency while protecting the prostate
09/14/2000WO1999063999A8 H1-histamine receptor antagonists
09/14/2000CA2367334A1 Compositions and methods for the treatment of tumors
09/14/2000CA2367315A1 Apoptosis inducing molecule ii and methods of use
09/14/2000CA2367144A1 Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
09/14/2000CA2367113A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2366706A1 Mammalian cytokines; related reagents and methods
09/14/2000CA2366689A1 Bifunctional molecules for delivery of therapeutics
09/14/2000CA2366644A1 Tyrosine kinase inhibitors
09/14/2000CA2366615A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2366602A1 Pyridoxal analogues for vitamin b-6 disorders
09/14/2000CA2366429A1 Methods and compositions for regulating memory consolidation
09/14/2000CA2366147A1 Casb618 polynucleotides and polypeptides and their use
09/14/2000CA2366087A1 Sialic acid-binding ig-like lectin (siglec) gene; ob-binding protein like (ob-bpl)
09/14/2000CA2365354A1 Methods and compositions for targeted drug delivery
09/14/2000CA2365230A1 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
09/14/2000CA2364252A1 Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
09/14/2000CA2362885A1 Human kallikrein-like genes
09/14/2000CA2362670A1 Matriptase, a serine protease and its applications
09/14/2000CA2362422A1 Polynucleotides and proteins encoded thereby
09/14/2000CA2362319A1 Imidazole compounds as histamine h3 ligands
09/14/2000CA2361849A1 Promotion or inhibition of angiogenesis and cardiovascularization
09/14/2000CA2361650A1 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
09/13/2000EP1034793A1 Preventives/remedies for glaucoma
09/13/2000EP1034299A1 Method for suppressing multiple drug resistance in cancer cells
09/13/2000EP1034295A1 ribA
09/13/2000EP1034276A1 Novel era
09/13/2000EP1034273A1 Histamine and serotonin binding molecules
09/13/2000EP1034265A1 Human cdc10 homolog
09/13/2000EP1034207A1 BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
09/13/2000EP1034002A1 Method for inhibiting premature rupture of fetal membranes, ripening of uterine cervix and preterm labor
09/13/2000EP1034001A1 Cd154 blockade therapy for therapeutic protein inhibitor syndrome
09/13/2000EP1033997A1 Method of mobilizing hematopoietic stem cells
09/13/2000EP1033985A1 Stable ascorbic acid preparation for topical use
09/13/2000EP1033982A1 Agents for combating neospora spec
09/13/2000EP1033981A1 Formulations and methods for reducing toxicity of antineoplastic agents
09/13/2000EP1033979A2 Cyp2a enzymes and their use in therapeutic and diagnostic methods
09/13/2000EP1033971A1 Combined chemo-immunotherapy with liposomal drugs and cytokines
09/13/2000EP0850050B1 Oral fast-dissolving compositions for dopamine agonists
09/13/2000EP0723439B1 Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women
09/13/2000EP0652776B1 Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them
09/13/2000CN1266459A Method and reagents for vaccination which generate a CD8 T cell immune response
09/13/2000CN1266456A Kinase activating dependent cyclin protein kinases, and their uses
09/12/2000US6117871 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
09/12/2000US6117868 Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
09/12/2000US6117855 Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
09/12/2000US6117849 S-(+)-adenosylmethionine and 3'-azido-2', 3'-dideoxy-nucleoside complexes as potent inhibitors of HIV-replication
09/12/2000US6117662 Respiratory nitrate reductase alpha subunit
09/12/2000US6117475 Fat based food products comprising sterols
09/12/2000US6117446 A buccal dosage unit for administering a combination of steroidal active agents, comprising a compressed tablet of a bioerodible polymeric carrier and an androgenic agent selected from testosterone and esters, progestin and esterogen
09/12/2000US6117445 Administration of an a1 adenosine receptor antagonist, or p2x purinoceptor or a compination of both offer potential as an antifibrotic or antisclerotic treatment
09/12/2000US6117421 Method for promoting cell growth and immunosuppression using chaperonin
09/09/2000CA2299205A1 Super-oxygenated water solutions and methods of use
09/08/2000WO2000052462A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
09/08/2000WO2000052210A2 Methods for targeting rna molecules
09/08/2000WO2000052198A1 Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
09/08/2000WO2000052057A1 Crystals and structural coordinate of protein complex and utilisation of the structural coordinate
09/08/2000WO2000052053A1 Antibodies against phosphomannan that are protective against candidiasis
09/08/2000WO2000052051A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
09/08/2000WO2000052046A1 Immunomodulating glycopeptide
09/08/2000WO2000051685A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
09/08/2000WO2000051642A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
09/08/2000WO2000051641A1 Pharmaceutical combination of antiviral agents
09/08/2000WO2000051640A1 Itchiness-relieving agents and itchiness-relieving effect potentiators
09/08/2000WO2000051620A1 Agents for intravitreal administration to treat or prevent disorders of the eye
09/08/2000WO2000051616A1 Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
09/08/2000WO2000051605A1 Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
09/08/2000WO2000051591A1 Combinations of formoterol and mometasone furoate for asthma
09/08/2000WO2000051589A2 VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF
09/08/2000WO2000051588A1 Compositions and methods for treatment of staphylococcal infection
09/08/2000WO2000051584A2 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
09/08/2000WO2000051583A2 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
09/08/2000WO2000051546A2 Bupropion metabolites and methods of their synthesis and use
09/08/2000WO2000027414A3 Inhibition of the formation of vascular hyperpermeability
09/08/2000WO2000027341A3 Novel method of treatment
1 ... 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 ... 1151